Kexing Biopharm Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	-	554.56	568.8	785.38	877.62
Cash & Short-Term Investments	612.79	554.56	568.8	785.38	877.62
Cash Growth	10.50%	-2.50%	-27.58%	-10.51%	-20.41%
Accounts Receivable	-	563.82	342.04	387.44	382.62
Other Receivables	-	15.9	4.45	3.25	2.84
Receivables	-	579.72	346.49	390.69	385.46
Inventory	-	141.81	191.36	208.18	172.16
Other Current Assets	-	11.72	26.97	27.06	25.57
Total Current Assets	-	1,288	1,134	1,411	1,461
Property, Plant & Equipment	-	1,177	1,200	1,053	936.24
Long-Term Investments	-	203.41	245.32	15	247.46
Other Intangible Assets	-	225.14	158.72	165.82	26.96
Long-Term Accounts Receivable	-	-	-	0.31	-
Long-Term Deferred Tax Assets	-	117.22	133.98	80.83	12.1
Long-Term Deferred Charges	-	50.37	3.08	-	21.82
Other Long-Term Assets	-	101.02	156.61	438.91	123.64
Total Assets	-	3,162	3,031	3,165	2,829
Accounts Payable	-	71.91	56.02	67.78	65.73
Accrued Expenses	-	112.98	84.14	92.89	97.63
Short-Term Debt	-	269.12	120.7	162.69	276.26
Current Portion of Long-Term Debt	-	313.25	275.03	51.78	-
Current Portion of Leases	-	12.45	6.7	19.87	18.39
Current Unearned Revenue	-	9.78	20.44	17.99	7.16
Other Current Liabilities	-	96.91	106.97	126.36	138.44
Total Current Liabilities	-	886.4	669.99	539.37	603.61
Long-Term Debt	-	611.18	695.84	779.23	263.37
Long-Term Leases	-	14.78	17.79	24.96	43.25
Long-Term Unearned Revenue	-	3.15	5.32	0.75	0.99
Long-Term Deferred Tax Liabilities	-	7.48	11.36	14.55	7.12
Total Liabilities	-	1,523	1,400	1,359	918.34
Common Stock	-	199.64	199.2	198.7	198.7
Additional Paid-In Capital	-	1,288	1,282	1,274	1,266
Retained Earnings	-	176.78	145.3	335.59	445.76
Treasury Stock	-	-31.12	-	-	-
Comprehensive Income & Other	-	1.11	-0.01	-	-
Total Common Equity	1,714	1,635	1,626	1,808	1,911
Minority Interest	-	4.34	4.77	-2.53	-
Shareholders' Equity	1,716	1,639	1,631	1,806	1,911
Total Liabilities & Equity	-	3,162	3,031	3,165	2,829
Total Debt	1,398	1,221	1,116	1,039	601.27
Net Cash (Debt)	-785.28	-666.22	-547.26	-253.16	276.35
Net Cash Growth	-	-	-	-	-64.88%
Net Cash Per Share	-3.99	-3.39	-2.76	-1.26	1.40
Filing Date Shares Outstanding	191.31	197.76	199.2	198.7	198.7
Total Common Shares Outstanding	198.11	197.76	199.2	198.7	198.7
Working Capital	-	401.41	463.63	871.94	857.2
Book Value Per Share	8.65	8.27	8.16	9.10	9.62
Tangible Book Value	1,478	1,410	1,467	1,643	1,884
Tangible Book Value Per Share	7.46	7.13	7.37	8.27	9.48
Buildings	-	754.25	662.95	609.2	361.78
Machinery	-	514.22	370.42	326.3	243.82
Construction In Progress	-	176.82	372.56	256.57	428.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.